Related references
Note: Only part of the references are listed.Genomic characterization of pulmonary-metastatic prostate cancer: A unique molecular subtype.
Eugene Shenderov et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
PTEN Mutations Trigger Resistance to Immunotherapy
Feixiong Cheng et al.
TRENDS IN MOLECULAR MEDICINE (2019)
Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations
Emmanuel S. Antonarakis et al.
EUROPEAN UROLOGY (2019)
A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer
Emmanuel S. Antonarakis
ONCOLOGIST (2019)
Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer
Michael C. Haffner et al.
AMERICAN JOURNAL OF PATHOLOGY (2018)
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
A. R. Hansen et al.
ANNALS OF ONCOLOGY (2018)
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
Yi-Mi Wu et al.
CELL (2018)
Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer
Harsimar B. Kaur et al.
MODERN PATHOLOGY (2018)
The long tail of oncogenic drivers in prostate cancer
Joshua Armenia et al.
NATURE GENETICS (2018)
Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer
Pedro Isaacsson Velho et al.
PROSTATE (2018)
Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer
Karim Boudadi et al.
Oncotarget (2018)
Microsatellite instability in prostate cancer and response to immune checkpoint blockade.
Wassim Abida et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).
Johann S. De Bono et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Diana Miao et al.
NATURE GENETICS (2018)
Cyclin-Dependent Kinase 12, Immunity, and Prostate Cancer
Emmanuel S. Antonarakis
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer (vol 128, pg 4441, 2018)
Daniel Nava Rodrigues et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis
Markus Mayrhofer et al.
GENOME MEDICINE (2018)
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy
Xiaohong Wang et al.
CANCER RESEARCH (2017)
Targeting DNA Repair in Cancer : Beyond PARP Inhibitors
Jessica S. Brown et al.
CANCER DISCOVERY (2017)
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Daniel Sanghoon Shin et al.
CANCER DISCOVERY (2017)
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
Tomasz M. Beer et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?
Giuseppe Palmieri et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2017)
Genomic hallmarks of localized, non-indolent prostate cancer
Michael Fraser et al.
NATURE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Phase II Study of Pembrolizumab (MK-3475) in Patients with metastatic castration-resistant Prostate Cancer (KEYNOTE-199)-Study AP 93/16 of the AUO
H. Rexer et al.
UROLOGE (2017)
Phase II Study of Pembrolizumab (MK-3475) in Patients with metastatic castration-resistant Prostate Cancer (KEYNOTE-199)-Study AP 93/16 of the AUO
H. Rexer et al.
UROLOGE (2017)
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Moshe Sade-Feldman et al.
NATURE COMMUNICATIONS (2017)
Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer
Christian D. Fankhauser et al.
Oncotarget (2017)
Treatment strategies for DNA repair-deficient prostate cancer
Benjamin A. Teply et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2017)
Cancer Statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Comprehensive Analysis of Hypermutation in Human Cancer
Brittany B. Campbell et al.
CELL (2017)
MSH2 Loss in Primary Prostate Cancer
Liana B. Guedes et al.
CLINICAL CANCER RESEARCH (2017)
The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer
Heidrun Gevensleben et al.
CLINICAL CANCER RESEARCH (2016)
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis
Francesco Massari et al.
TARGETED ONCOLOGY (2016)
Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
Keisuke Kataoka et al.
NATURE (2016)
Classification and characterization of microsatellite instability across 18 cancer types
Ronald J. Hanse et al.
NATURE MEDICINE (2016)
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
C. C. Pritchard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate
Michael T. Schweizer et al.
ONCOTARGET (2016)
TGFβ-dependent expression of PD-1 and PD-L1 controls CD8+ T cell anergy in transplant tolerance
Marije Baas et al.
ELIFE (2016)
Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors
Sherri Z. Millis et al.
JAMA ONCOLOGY (2016)
Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy
Sander Kelderman et al.
CANCER CELL (2015)
Integrative Clinical Genomics of Advanced Prostate Cancer (vol 161, pg 1215, 2015)
Dan Robinson et al.
CELL (2015)
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan Robinson et al.
CELL (2015)
The Molecular Taxonomy of Primary Prostate Cancer
Adam Abeshouse et al.
CELL (2015)
Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study
Paul J. Goodfellow et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
MSIplus for Integrated Colorectal Cancer Molecular Testing by Next-Generation Sequencing
Jennifer A. Hempelmann et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Yoshinari Asaoka et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
Jennifer L. Bishop et al.
ONCOTARGET (2015)
Milestones of Lynch syndrome: 1895-2015
Henry T. Lynch et al.
NATURE REVIEWS CANCER (2015)
Prostate cancer incidence in males with Lynch syndrome
Sigurdis Haraldsdottir et al.
GENETICS IN MEDICINE (2014)
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon et al.
LANCET ONCOLOGY (2014)
Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer
Colin C. Pritchard et al.
NATURE COMMUNICATIONS (2014)
Elevated Risk of Prostate Cancer Among Men With Lynch Syndrome
Victoria M. Raymond et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
Colorectal and Other Cancer Risks for Carriers and Noncarriers From Families With a DNA Mismatch Repair Gene Mutation: A Prospective Cohort Study
Aung Ko Win et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Risks of Primary Extracolonic Cancers Following Colorectal Cancer in Lynch Syndrome
Aung Ko Win et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Hereditary prostate cancer as a feature of Lynch Syndrome
Christina M. Bauer et al.
FAMILIAL CANCER (2011)
Genetic counselling for hereditary predisposition to ovarian and breast cancer
J. Mackay et al.
ANNALS OF ONCOLOGY (2010)
Microsatellite Instability in Colorectal Cancer
C. Richard Boland et al.
GASTROENTEROLOGY (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Germ-Line Mutations in Mismatch Repair Genes Associated with Prostate Cancer
Eli Marie Grindedal et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2009)
EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome
Glenn E. Palomaki et al.
GENETICS IN MEDICINE (2009)
Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells
Joseph F. Grosso et al.
JOURNAL OF IMMUNOLOGY (2009)
Differences and evolution of the methods for the assessment of microsatellite instability
L. Laghi et al.
ONCOGENE (2008)
Localized prostate cancer
Patrick C. Walsh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Clinically localised prostate cancer is microsatellite stable
Abdel-Rahmene Azzouzi et al.
BJU INTERNATIONAL (2007)
HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression
Jan Willem F. Dierssen et al.
BMC CANCER (2007)
What should a urologist know about hereditary predisposition to prostate cancer?
Ola Bratt
BJU INTERNATIONAL (2007)
TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
DA Thomas et al.
CANCER CELL (2005)
Development of a fluorescent multiplex assay for detection of MSI-high tumors
JW Bacher et al.
DISEASE MARKERS (2004)
The clinical importance and prognostic implications of microsatellite instability in sporadic cancer
DA Lawes et al.
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY (2003)
Genomic medicine - Hereditary colorectal cancer
HT Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Genome maintenance mechanisms for preventing cancer
JHJ Hoeijmakers
NATURE (2001)
Share Paper
